Georges M Haidar1, Taylor D Hicks1, Hosam F El-Sayed2, Mark G Davies3. 1. Division of Vascular and Endovascular Surgery, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex; South Texas Center for Vascular Care, University Hospital System, San Antonio, Tex. 2. Division of Vascular Diseases and Surgery, Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, Ohio. 3. Division of Vascular and Endovascular Surgery, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex; South Texas Center for Vascular Care, University Hospital System, San Antonio, Tex. Electronic address: daviesm@uthscsa.edu.
Abstract
OBJECTIVE: Advanced renal cell carcinoma (RCC) has a significant predisposition to vascular invasion. Tumor vascular invasion and thrombus are found in the renal vein and the inferior vena cava (IVC) in up to 10% to 25% of patients. This study reviewed the current status of radical nephrectomy with IVC thrombectomy for advanced RCC. METHODS: A two-level search strategy of the literature (MEDLINE, PubMed, The Cochrane Library, and Google Scholar) for relevant articles listed between January 2000 and December 2015 was performed. The review was confined to patients with primary RCC associated with vascular invasion. RESULTS: Untreated RCC with intravascular thrombus has a median survival of 5 months. Surgical exposure and intervention are tailored to the level of tumor thrombus. The 30-day mortality for radical nephrectomy with IVC thrombectomy is low (1.5%-10%), and the complication rates have been reported to be 18%, 20%, 26%, and 47% for IVC tumor thrombus level I, II, III, and IV disease, respectively. Disease-specific survival ranges from 40% to 60% at 5 years after nephrectomy and removal of the intravascular tumor. CONCLUSIONS: Radical nephrectomy with IVC thrombectomy is an effective cancer control operation that can be safely performed with acceptable mortality and morbidity. Preoperative imaging coupled with perioperative surgical management of the IVC is critical to procedural success and patient outcomes.
OBJECTIVE: Advanced renal cell carcinoma (RCC) has a significant predisposition to vascular invasion. Tumor vascular invasion and thrombus are found in the renal vein and the inferior vena cava (IVC) in up to 10% to 25% of patients. This study reviewed the current status of radical nephrectomy with IVC thrombectomy for advanced RCC. METHODS: A two-level search strategy of the literature (MEDLINE, PubMed, The Cochrane Library, and Google Scholar) for relevant articles listed between January 2000 and December 2015 was performed. The review was confined to patients with primary RCC associated with vascular invasion. RESULTS: Untreated RCC with intravascular thrombus has a median survival of 5 months. Surgical exposure and intervention are tailored to the level of tumor thrombus. The 30-day mortality for radical nephrectomy with IVC thrombectomy is low (1.5%-10%), and the complication rates have been reported to be 18%, 20%, 26%, and 47% for IVC tumor thrombus level I, II, III, and IV disease, respectively. Disease-specific survival ranges from 40% to 60% at 5 years after nephrectomy and removal of the intravascular tumor. CONCLUSIONS: Radical nephrectomy with IVC thrombectomy is an effective cancer control operation that can be safely performed with acceptable mortality and morbidity. Preoperative imaging coupled with perioperative surgical management of the IVC is critical to procedural success and patient outcomes.
Authors: Gregory J Nason; Khaled Ajib; Guan Hee Tan; Dixon T S Woon; George T Christakis; Robert K Nam Journal: Can Urol Assoc J Date: 2021-04 Impact factor: 1.862
Authors: Alberto C Pieretti; Manuel Ozambela; Mary E Westerman; Graciela M Nogueras-Gonzalez; Luis A Segarra; Niki M Zacharias; Ara Vaporciyan; Wayne Hofstetter; Tam Huynh; Saad Aldousari; Surena F Matin; Jose A Karam Journal: Clin Genitourin Cancer Date: 2022-02-09 Impact factor: 3.121
Authors: Zuzanna Horynecka; Beata Jabłońska; Adam Kurek; Andrzej Lekstan; Michał Piaszczyński; Sławomir Mrowiec; Grzegorz Oczkowicz; Robert Król Journal: Medicine (Baltimore) Date: 2022-10-07 Impact factor: 1.817